These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12742487)

  • 1. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients.
    Morrisett JD; Abdel-Fattah G; Kahan BD
    Transplant Proc; 2003 May; 35(3 Suppl):143S-150S. PubMed ID: 12742487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients.
    Morrisett JD; Abdel-Fattah G; Hoogeveen R; Mitchell E; Ballantyne CM; Pownall HJ; Opekun AR; Jaffe JS; Oppermann S; Kahan BD
    J Lipid Res; 2002 Aug; 43(8):1170-80. PubMed ID: 12177161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients.
    Hoogeveen RC; Ballantyne CM; Pownall HJ; Opekun AR; Hachey DL; Jaffe JS; Oppermann S; Kahan BD; Morrisett JD
    Transplantation; 2001 Oct; 72(7):1244-50. PubMed ID: 11602850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression enhances atherogenicity of lipid profile after transplantation.
    Quaschning T; Mainka T; Nauck M; Rump LC; Wanner C; Krämer-Guth A
    Kidney Int Suppl; 1999 Jul; 71():S235-7. PubMed ID: 10412786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment.
    Maluf DG; Mas VR; Archer KJ; Yanek K; King A; Ferreira-Gonzalez A; Fisher RA; Posner M
    Transplantation; 2005 Dec; 80(12):1705-11. PubMed ID: 16378065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.
    Ichimaru N; Takahara S; Kokado Y; Wang JD; Hatori M; Kameoka H; Inoue T; Okuyama A
    Atherosclerosis; 2001 Oct; 158(2):417-23. PubMed ID: 11583721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
    Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
    Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients.
    Wheeler DC; Morgan R; Thomas DM; Seed M; Rees A; Moore RH
    Transpl Int; 1996; 9(3):221-6. PubMed ID: 8723190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A.
    Massy ZA; De Bandt JP; Morelon E; Thevenin M; Lacour B; Kreis H
    Nephrol Dial Transplant; 2000 Jun; 15(6):928. PubMed ID: 10831671
    [No Abstract]   [Full Text] [Related]  

  • 11. Relationship of cyclosporin and sirolimus blood concentrations regarding the incidence and severity of hyperlipidemia after kidney transplantation.
    Spinelli GA; Felipe CR; Machado PG; Garcia R; Casarini DE; Moreira SR; Park SI; Tedesco-Silva H; Medina-Pestana JO
    Braz J Med Biol Res; 2006 Jan; 39(1):19-30. PubMed ID: 16400461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
    Trotter JF; Wachs ME; Trouillot TE; Bak T; Kugelmas M; Kam I; Everson G
    Liver Transpl; 2001 May; 7(5):401-8. PubMed ID: 11349259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients. A comparative study.
    Fernández-Miranda C; de la Calle A; Morales JM; Guijarro C; Aranda JL; Gómez-Sanz R; Gómez-Izquierdo T; Larumbe S; Moreno E; Rodicio JL; del Palacio A
    Clin Transplant; 1998 Apr; 12(2):136-41. PubMed ID: 9575402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.
    Langer RM; Hong DM; Katz SM; Van Buren CT
    Transplant Proc; 2002 Dec; 34(8):3162-4. PubMed ID: 12493406
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation of C0 and C2 levels with lipid profiles in adolescent renal transplant recipients in the early and late posttransplant periods.
    Soylu A; Kavukçu S; Türkmen MA; Kasap B; Soylu A; Bora S; Gülay H
    Transplant Proc; 2006 Jun; 38(5):1286-9. PubMed ID: 16797283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations.
    Tory R; Sachs-Barrable K; Goshko CB; Hill JS; Wasan KM
    Transplantation; 2009 Jul; 88(1):62-8. PubMed ID: 19584682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pancreas transplantation on lipoprotein lipase, postprandial lipemia, and HDL cholesterol.
    Föger B; Königsrainer A; Palos G; Brandstätter E; Ritsch A; König P; Miesenböck G; Lechleitner M; Margreiter R; Patsch JR
    Transplantation; 1994 Oct; 58(8):899-904. PubMed ID: 7940733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty.
    Tedesco Silva H; Felipe CR; Machado PG; Garcia R; Motegi S; Hosaka BH; Hanzawa NM; Park SI; Casarini D; Lima VC; Franco M; Medina-Pestana JO
    Transplant Proc; 2003 May; 35(3 Suppl):177S-180S. PubMed ID: 12742493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids.
    Akman B; Uyar M; Afsar B; Sezer S; Ozdemir FN; Haberal M
    Transplant Proc; 2007; 39(1):135-7. PubMed ID: 17275490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.